GlassScriptPhysician profile
Rajaratnam T Abraham
NPI 1891799748
$1,187.90
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,157 · 2020: $31.02.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $219.11 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $212.37 | 2019 | |
| Novo Nordisk INC | $135.28 | 2019 | |
| Janssen Pharmaceuticals, INC | $121.44 | 2019 | |
| Pfizer INC. | $79.33 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.88 | 2019 | |
| Lilly USA, LLC | $62.24 | 2019 | |
| Sanofi-Aventis U.S. LLC | $55.31 | 2019 | |
| Astellas Pharma US INC | $34.64 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.23 | 2019-2020 | |
| Glaxosmithkline, LLC. | $30.12 | 2019 | |
| Merck Sharp & Dohme LLC | $29.82 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.87 | 2019 | |
| Circassia INC. | $17.69 | 2019 | |
| Mylan Specialty L.P. | $16.91 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $15.71 | 2019 | |
| Advanced Respiratory, INC | $15.35 | 2020 | |
| Allergan, INC. | $11.84 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.76 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajaratnam Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.